Currently out of the existing stock ratings of Li Watsek, 87 are a BUY (95.6%), 4 are a HOLD (4.4%).

Li Watsek

Work Performance Price Targets & Ratings Chart

Analyst Li Watsek, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 34.48% that have a potential upside of 31.34% achieved within 106 days.

Li Watsek’s has documented 158 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ASND, Ascendis Pharma AS at 11-May-2025.

Wall Street Analyst Li Watsek

Analyst best performing recommendations are on FATE (FATE THERAPEUTICS).
The best stock recommendation documented was for CRVS (CORVUS PHARMACEUTICALS) at 8/3/2021. The price target of $5 was fulfilled within 45 days with a profit of $2.9 (138.1%) receiving and performance score of 30.69.

Average potential price target upside

of $45.78 (42.13%) on ASND (ASCENDIS PHARMA AS).
of $20.05 (72.21%) on VINC (VINCERX PHARMA).
of $2.8 (213.92%) on CRVS (CORVUS PHARMACEUTICALS).

CRVS Corvus Pharmaceuticals SLS Sellas Life Sciences Group AFMD Affimed NV VINC Vincerx Pharma ARVN Arvinas ASND Ascendis Pharma AS PRTG Portage Biotech ONCT Oncternal Therapeutics NKTX Nkarta APTO Aptose Biosciences GBT Global Blood Therapeutics ALXO Alx Oncology Holdings BCYC Bicycle Therapeutics Ltd FATE Fate Therapeutics KURA Kura Oncology RCUS Arcus Biosciences CRIS Curis IDYA Ideaya Biosciences YMAB Y mAbs Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Graig Suvannavejh (MIZUHO)